A Simple but Accurate Method for Evaluating Drug-Resistance in Infectious HCVcc System

Table 3

Anti-HCV activities of drugs against WT and mutant HCV in Huh7.5 cells.

HCV	Inhibitor	EC50 (μM)	Changed fold
WT	Telaprevir	0.01 ± 0.01	—
WT	Simeprevir	0.01 ± 0.01	—
WT	Sofosbuvir	0.08 ± 0.04	—
D168V	Simeprevir	0.94 ± 0.85	94.0
H118R	Sofosbuvir	0.03 ± 0.05	0.38
N335S	Sofosbuvir	0.01 ± 0.01	0.13
E333G	Sofosbuvir	0.01 ± 0.01	0.13
E333G/N335S	Sofosbuvir	0.02 ± 0.01	0.25
A156T	Telaprevir	0.54 ± 0.37	54.0
A156T	Simeprevir	0.01 ± 0.01	1.0
A156T	Sofosbuvir	0.11 ± 0.16	1.4
S282T	Sofosbuvir	0.52 ± 0.37	6.5
S282T	Simeprevir	0.01 ± 0.01	1.0

The anti-HCV activities of drugs against wild type (WT) and mutant HCV were detected in Huh7.5 cells infected with HCV 2a. The EC₅₀ was calculated with the Reed-Muench method after intracellular HCV RNA was detected with qRT-PCR. Data presented are means ± standard deviation from over 3 independent experiments. Changed fold was the ratio of the EC₅₀ of WT against that of mutant HCV.